Medpace's second quarter 2026 results beat estimates, driven by a 28.2% surge in net new business awards.

Medpace reported second quarter 2026 revenue of $707.3 million, up 17.2% year-over-year, with diluted EPS of $4.25, a 37.1% increase from the prior-year period. Both revenue and EPS surpassed analyst expectations.

Key Highlights

• Net new business awards rebounded significantly, growing 28.2% year-over-year to $795.7 million, which resulted in a strong book-to-bill ratio of 1.13x.
• Second quarter revenue growth of 17.2% was driven by a backlog conversion rate of 24.1%, exceeding consensus estimates.
• The company introduced full-year 2026 revenue guidance in the range of $2.805 billion to $2.885 billion and diluted EPS guidance between $17.25 and $17.95.